Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. - Test2 - elhamkhani - TriplyDB

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

http://www.wikidata.org/entity/Q37984574

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Mechanism of Anti-α-Synuclein Immunotherapy Diverse molecular targets for therapeutic strategies in Alzheimer's disease Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?Intravenous immunoglobulin and Alzheimer's disease: what now?Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Immunotherapeutic approaches for Alzheimer's disease Alzheimer's disease: Unique markers for diagnosis & new treatment modalities Vaccines, new opportunities for a new society.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process.Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease Amyloid-beta: a crucial factor in Alzheimer's disease.Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunction Novel immunological approaches for the treatment of Alzheimer's disease.Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).Microstate connectivity alterations in patients with early Alzheimer's disease.An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease.Amyloid-β positron emission tomography imaging probes: a critical review.Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment.Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.What does complement do in Alzheimer's disease? Old molecules with new insights.Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.Plant-based vaccines for Alzheimer's disease: an overview.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Alzheimer's disease and immunotherapy: what is wrong with clinical trials?First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.

P2860

Q26739412-B97FBE7C-723B-45FE-A5A3-597E7ED90824 Q26749755-2342D9FB-017D-4394-AA90-73C26253C3D7 Q26772943-7DE06C4E-11C8-4713-90C7-D15B9ACB3007 Q26827193-A0C1F3D6-8FAE-4000-9EE1-585E8AFA5285 Q26859305-B33FFF71-CD6E-4083-B443-77E1490AF819 Q27000371-7462DC67-A2C7-4BD3-9C6C-5D189CB5F7DE Q28077869-3170CDF9-9354-463E-A9D9-F4E9F88C35A1 Q28081278-7577BF9B-5522-4098-8F42-C7063DC2FD57 Q28085139-499DFBE9-F5BB-46E4-A6A5-9FB57100C4EE Q30390904-D25E210D-F600-4AF4-B76D-FAAB09822AC3 Q30651551-1231D5C6-E701-4611-8CA2-F131E4ED96AC Q34020079-6B74DBEC-67DB-4FAC-B35B-18177E734FCA Q34095163-3F6BC8D5-8BC3-4802-87DB-3301D27AE794 Q34451907-D279210A-0104-4FB9-8FE2-ACDE0B247D38 Q34531520-D7AD2EC5-3081-4471-8C49-A40C01C7CFCD Q34562675-2F8DA7F5-B80F-46B6-A604-68659A16BD26 Q34566355-2BF05A6E-B184-4628-AE8B-4D6145EC8482 Q36103515-91170BCA-FEEA-475E-92E7-722A7EB052B1 Q36419603-C630F5AB-338A-4C3F-865C-10A36656025C Q36685236-87D81D11-1C9F-4D08-92D2-F9056C4989B8 Q36768052-98754356-5939-4ED5-A6D6-606D59620584 Q37086266-8C4EDD7E-3CF9-46E1-9726-B53267F5A72E Q37141684-8BAE6EF3-6793-465E-BA0D-75005F5A3D32 Q37364347-C8D59548-E934-489A-9BD5-E2698775F4A5 Q37364350-1DD1A2D4-E00D-427E-95F6-AFF2ECEE2274 Q37368120-7FE4750D-BAE8-4B0E-979B-BEEC7ADFC14E Q37435886-9A8C38F4-C85B-4814-89D6-6827F19BAD93 Q37501943-C732B305-3216-4A72-A968-467B5E3AA28C Q37530061-C1094F6B-4D22-4A6B-9713-3F0036303C94 Q38079317-CD0AD9B6-65E7-4331-A766-DB139A2478E2 Q38102579-CA749F0E-4B7E-4615-8F38-830907EB4AB4 Q38176962-3B50F4DB-90B0-41A5-A706-11E13235215E Q38184618-616A1825-F834-43C0-8B57-61697A5EED7F Q38224958-950E8476-E2AF-4ECD-9CD1-6671593D7348 Q38400601-66770FF3-F842-45B3-9301-4833A301D774 Q38569669-D1F42225-078A-46D1-95E1-DD2A208F382C Q38715233-C8266B97-6209-4172-9E41-4C2EC39DCD8B Q38912275-3FFFCBE0-FA2D-463D-80F9-3244B79F49D0 Q39083050-E01CA731-E29D-497C-B0EF-FD6129E90F45 Q41846962-BBEB6B0E-1617-429A-B12B-9DA21386EF8D

P2860

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

http://www.wikidata.org/entity/Q37984574

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunotherapy for Alzheimer's ...... based immunization strategies.

@en

Immunotherapy for Alzheimer's ...... based immunization strategies.

@nl

type

label

Immunotherapy for Alzheimer's ...... based immunization strategies.

@en

Immunotherapy for Alzheimer's ...... based immunization strategies.

@nl

prefLabel

Immunotherapy for Alzheimer's ...... based immunization strategies.

@en

Immunotherapy for Alzheimer's ...... based immunization strategies.

@nl

P1433

Q37984574-B3AA2F2B-547F-4B25-856C-4546F4F3D345

P1476

Q37984574-B0F46E89-E343-4AF8-BF2B-D308B10E2449

P2093

Q37984574-16E327BD-3A44-4B47-80A4-BE3717041195

Q37984574-5D558231-4DCA-4990-BFEA-8030CC3724DE

Q37984574-B7AFD488-002E-40CB-B92E-54247E9DF68C

Q37984574-C5A9D2A5-8BB3-456E-91B4-E33E72B54629

Q37984574-EAEBBE6A-6A75-454D-8274-9DA91267DBDE

Q37984574-F1E559B1-3FA0-4447-BDE6-82C4392B5B79

P2860

Q37984574-01F35A7F-0102-4640-A3FF-1567DE661F6E

Q37984574-02306365-3BFF-4E98-9B7A-E9365B592DEE

Q37984574-02D54F82-AA80-4793-9999-781B725FB3F2

Q37984574-03EB9E94-FC26-4A13-A9B1-E6F55EA70D2A

Q37984574-050D4AFC-528C-48AE-8B3C-E4CB160E40FD

Q37984574-0524BEA2-1113-4500-B5AE-654E2F3F43FE

Q37984574-05DBA157-0AEE-4F2F-B68A-A321655774F6

Q37984574-0679F518-1F43-4429-BFF9-9A57893DDFE9

Q37984574-0714408F-649E-452C-AEBC-0C1FC165FF60

Q37984574-0A620440-D492-4FBC-838D-82B2CAB0AED9

P304

Q37984574-AC461236-8F04-4294-9BD7-086FEE633338

P31

Q37984574-9FFD9FFB-7238-4E74-8470-650E048AD30C

P356

Q37984574-893ABDBA-B1FF-4C8F-9D83-7F25A19431B9

P433

Q37984574-4DF33FC8-F702-4917-BEBE-FDE54AAB5730

P478

Q37984574-43B1719E-82AF-43F1-BBF2-73A7C05A298C

P50

Q37984574-1F4BCAC7-E0E9-4416-A5E2-D9F425FF515F

Q37984574-50A0761F-CAFD-478F-82AC-ABE932232E01

Q37984574-FC336378-FC96-4D29-B098-869814C16B3A

P577

Q37984574-919ECB16-FA25-4095-82A9-D0DA18E71F25

P5875

Q37984574-AF27C938-2714-4507-9C63-8E2F390264AB

P698

Q37984574-5D3A82D1-2643-4E17-804D-C9A01EFEBC40

P921

Q37984574-84A9A23E-E13F-488A-92DA-3A99E2C15BC3

Q37984574-9AD65930-B5E2-4222-B6AE-1C186F28D510

Q37984574-EE773732-92BD-4F1C-A2CB-FF6DB1A99AA5

P356

P1433

P1476

Immunotherapy for Alzheimer's ...... -based immunization strategies

@en

P2093

Alberto Pilotto

http://www.w3.org/2001/XMLSchema#string

Andrea Santamato

http://www.w3.org/2001/XMLSchema#string

Antonio Greco

http://www.w3.org/2001/XMLSchema#string

Davide Seripa

http://www.w3.org/2001/XMLSchema#string

Giancarlo Logroscino

http://www.w3.org/2001/XMLSchema#string

Vincenzo Solfrizzi

http://www.w3.org/2001/XMLSchema#string

P2860

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo

Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease

Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum

Active and passive immunotherapy for neurodegenerative disorders

Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease

P304

213-238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.11.170

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Panza

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221837102

http://www.w3.org/2001/XMLSchema#string

P698

22339463

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease